Pharmaceutical Wholesale Distribution & Healthcare Services
Strategic Profile
Incorporated in 2009 and headquartered in Setagaya, Japan, Vital KSK operates as a diversified healthcare and pharmaceutical distribution player in the Japanese market. The company maintains a stable operational profile with a market cap of approximately ¥61.985B and a P/E ratio of 8.73, indicating attractive valuation multiples for dividend-focused investors.
Cyborg Score Rationale
Vital KSK demonstrates solid fundamentals with a strong balance sheet, attractive valuation, and stable dividend yield. However, the company faces modest growth momentum and corporate governance concerns, with limited board independence constraining investment appeal.
Top Insights
Strong dividend profile with 3.76% yield, appealing to risk-averse Japanese investors
Trading at significant discount to fair value with low P/E multiple of 8.73x
Diversified revenue streams across pharma wholesale, elderly care, insurance, and consulting reduce concentration risk
Limited board independence (2 of 10 independent directors) and governance gaps may concern institutional investors
Named Competitors
Pharmaceutical Wholesale & Distribution — Japan's largest pharmaceutical distributor
Medical Distribution — Diversified pharmaceutical and medical equipment distributor
Healthcare Services — Integrated pharmaceutical distribution and consulting
Recent Developments
(March 2026) Stock trading at ¥1,219-1,399 JPY with modest volatility
(2025) Market cap approximately ¥61.985B with earnings scheduled for August reporting
(2022) Announced share repurchase program of up to 1.5M shares targeting capital efficiency
Open the full interactive Vital KSK Holdings, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.